Scaffolding Protein Targeting, Isoform Selectivity, and PPI Inhibitor Development for Oncology & Neurobiology
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for 14-3-3 Epsilon drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | YWHAE (14-3-3 Epsilon) Recombinant Protein Sequence Verified, High Purity (>95%), Theoretical MW 28.2 kDa. GST- or His-tag options. |
View YWHAE Products |
| Antigen (Mutant) | YWHAE R56/60A Mutant Protein Phosphopeptide-binding deficient variant for mechanism validation. |
View YWHAE Products |
| Isoform Panel | 14-3-3 Family Ortholog Set YWHAB, YWHAG, YWHAZ, SFN for selectivity counter-screening. |
View YWHAB Products, View YWHAG Products, View YWHAZ Products, View SFN Products |
| Gene Delivery | YWHAE Lentivirus Particles Full-length ORF for stable cell line construction, CMV promoter. |
View YWHAE Products |
| Validator | YWHAE siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View YWHAE Products |
| Fusion Partner | NUTM2B Protein Relevant for YWHAE-NUTM2 fusion studies in endometrial stromal sarcoma. |
View NUTM2B Products |
| Pathway Partner | RAF1 Protein Classical 14-3-3 binding partner for co-crystallization assays. |
View RAF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (7 mammalian 14-3-3 isoforms) | Complete isoform panel (YWHAE, YWHAB, YWHAG, YWHAZ, SFN, YWHAH, YWHAQ) with >95% purity, sequence-verified by mass spec for absolute discrimination |
| Mechanism Validation (Phospho-binding vs Dimerization) | Site-specific mutants available: R56/60A (phospho-binding deficient), L220P (dimerization disrupted) |
| Intracellular Target Engagement | Cell-permeable recombinant proteins and lentivirus systems for cellular validation; HEK293 expressed with native post-translational modifications |
| False Positives in PPI Assays | Validated siRNA included for specificity checks; phosphopeptide competitors available |
Live YWHAE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The 14-3-3 protein family, particularly the Epsilon isoform (YWHAE), has emerged from a passive scaffolding role to a validated therapeutic node in oncology and neurodevelopmental disorders. The discovery of oncogenic YWHAE-NUTM2A/B fusions in high-grade endometrial stromal sarcoma has catalyzed precision oncology efforts targeting the underlying PPI dysregulation.
Current R&D focuses on disrupting 14-3-3/client protein interactions using:
- Isoform-selective small molecules targeting the amphipathic binding groove
- Stapled peptides mimicking client protein phosphorylated motifs
- Molecular glues that stabilize non-native protein complexes
The race for YWHAE therapeutics is intensifying, with major players shifting focus from pan-14-3-3 inhibitors to isoform-selective modulators. As first-generation molecules enter preclinical validation, the next wave of R&D is targeting fusion protein degradation and allosteric sites distal to the phosphopeptide-binding pocket.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitor | Academic consortia, Biotech | Endometrial Stromal Sarcoma (YWHAE-fusions) | Isoform Selectivity Panel (Need YWHAE vs YWHAB/YWHAG/YWHAZ) |
| Stapled Peptide | Aileron Therapeutics (adjacent) | Solid Tumors (p53/MDM2 pathway) | Competitive Binding Assay (Need high-purity WT and mutant YWHAE) |
| Molecular Glue | Pharma R&D | Hematological Malignancies | Ternary Complex Formation (Need YWHAE + Client + Ligand) |
| PROTAC | Emerging biotech | Fusion-driven cancers | Cell-based degradation (Need Lentivirus for stable YWHAE-fusion expression) |